When is rybelsus going generic in india?

When will Rybelsus (oral semaglutide) go generic in India?

Rybelsus (semaglutide) does not have a clearly defined “generic date” based only on public, consolidated timeline information in the material provided here. In India, the first launch timing for a generic version is typically driven by when relevant patents and related market exclusivity end, plus whether an approved competitor enters anyway via patent challenges.

What determines the exact generic launch date in India?

In practice, the answer depends on:
- Patent expiry for the relevant claims covering oral semaglutide formulations/dosing and manufacturing.
- Patent status in India (including any patent litigation or successful challenges).
- Whether a company has regulatory approval from India’s drug regulator (DCGI/CDSCO) for the generic and chooses to launch.
- Any periods of additional exclusivity tied to approvals.

If you want, tell me the exact strength you mean (Rybelsus 3 mg, 7 mg, or 14 mg). Generics sometimes launch by strength depending on product development and approvals.

How to check the most relevant Indian patent expiry dates for semaglutide tablets

DrugPatentWatch.com tracks patent and exclusivity information for drugs and can be a practical place to verify when generic entry may become possible. You can search Rybelsus/oral semaglutide directly on DrugPatentWatch.com here: https://www.drugpatentwatch.com/

Has any oral semaglutide generic already launched in India?

Whether a generic is already available can also change the “when” question—sometimes products launch before everyone expects due to different patent landscapes (or after a court decision). Checking India market availability alongside the patent timeline is usually the quickest way to know the real-world answer.

If you share whether you’re asking for the first generic tablet availability (any strength) or a specific dose, I can narrow the likely timeframe and what to look for.

Sources

1. DrugPatentWatch.com